Literature DB >> 17090653

Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice.

Andrew Kim1, Kelly Morgan, Diane E Hasz, Stephen M Wiesner, Jennifer O Lauchle, Jennifer L Geurts, Miechaleen D Diers, Doan T Le, Scott C Kogan, Luis F Parada, Kevin Shannon, David A Largaespada.   

Abstract

Neurofibromatosis type 1 (NF1) syndrome is caused by germline mutations in the NF1 tumor suppressor, which encodes neurofibromin, a GTPase activating protein for Ras. Children with NF1 are predisposed to juvenile myelomonocytic leukemia (JMML) and lethally irradiated mice given transplants with homozygous Nf1 mutant (Nf1-/-) hematopoietic stem cells develop a fatal myeloproliferative disorder (MPD) that models JMML. We investigated the requirement for signaling through the GM-CSF receptor to initiate and sustain this MPD by generating Nf1 mutant hematopoietic cells lacking the common beta chain (Beta c) of the GM-CSF receptor. Mice reconstituted with Nf1-/-, beta c-/- stem cells did not develop evidence of MPD despite the presence of increased number of immature hematopoietic progenitors in the bone marrow. Interestingly, when the Mx1-Cre transgene was used to inactivate a conditional Nf1 mutant allele in hematopoietic cells, concomitant loss of beta c-/- reduced the severity of the MPD, but did not abrogate it. Whereas inhibiting GM-CSF signaling may be of therapeutic benefit in JMML, our data also demonstrate aberrant proliferation of Nf1-/-myeloid progenitors that is independent of signaling through the GM-CSF receptor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17090653      PMCID: PMC1794059          DOI: 10.1182/blood-2006-05-025395

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

Review 1.  Atypical cellular disorders.

Authors:  Robert J Arceci; B Jack Longley; Peter D Emanuel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2002

2.  The neurofibromatosis type 1 gene encodes a protein related to GAP.

Authors:  G F Xu; P O'Connell; D Viskochil; R Cawthon; M Robertson; M Culver; D Dunn; J Stevens; R Gesteland; R White
Journal:  Cell       Date:  1990-08-10       Impact factor: 41.582

3.  Neurofibromas in NF1: Schwann cell origin and role of tumor environment.

Authors:  Yuan Zhu; Pritam Ghosh; Patrick Charnay; Dennis K Burns; Luis F Parada
Journal:  Science       Date:  2002-05-03       Impact factor: 47.728

4.  Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain.

Authors:  Y Zhu; M I Romero; P Ghosh; Z Ye; P Charnay; E J Rushing; J D Marth; L F Parada
Journal:  Genes Dev       Date:  2001-04-01       Impact factor: 11.361

5.  Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis.

Authors:  J E DeClue; A G Papageorge; J A Fletcher; S R Diehl; N Ratner; W C Vass; D R Lowy
Journal:  Cell       Date:  1992-04-17       Impact factor: 41.582

6.  Nf1 and Gmcsf interact in myeloid leukemogenesis.

Authors:  R A Birnbaum; A O'Marcaigh; Z Wardak; Y Y Zhang; G Dranoff; T Jacks; D W Clapp; K M Shannon
Journal:  Mol Cell       Date:  2000-01       Impact factor: 17.970

7.  Quantitative effects of Nf1 inactivation on in vivo hematopoiesis.

Authors:  Y Zhang; B R Taylor; K Shannon; D W Clapp
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

8.  Malignancy in neurofibromatosis.

Authors:  D G Hope; J J Mulvihill
Journal:  Adv Neurol       Date:  1981

9.  Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

Authors:  Doan T Le; Namie Kong; Yuan Zhu; Jennifer O Lauchle; Abigail Aiyigari; Benjamin S Braun; Endi Wang; Scott C Kogan; Michelle M Le Beau; Luis Parada; Kevin M Shannon
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

10.  Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells.

Authors:  Tamiko R Katsumoto; Jennifer Duda; Andrew Kim; Zabihullah Wardak; Glenn Dranoff; D Wade Clapp; Kevin Shannon
Journal:  J Exp Med       Date:  2005-03-21       Impact factor: 14.307

View more
  17 in total

1.  Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5.

Authors:  Wenbin Xiao; Hong Hong; Yuko Kawakami; Clifford A Lowell; Toshiaki Kawakami
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

2.  Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Authors:  Zohar Sachs; Raha A Been; Krista J DeCoursin; Hanh T Nguyen; Nurul A Mohd Hassan; Klara E Noble-Orcutt; Craig E Eckfeldt; Emily J Pomeroy; Ernesto Diaz-Flores; Jennifer L Geurts; Miechaleen D Diers; Diane E Hasz; Kelly J Morgan; Margaret L MacMillan; Kevin M Shannon; David A Largaespada; Stephen M Wiesner
Journal:  Haematologica       Date:  2016-07-14       Impact factor: 9.941

Review 3.  Targeting oncogenic Ras signaling in hematologic malignancies.

Authors:  Ashley F Ward; Benjamin S Braun; Kevin M Shannon
Journal:  Blood       Date:  2012-08-16       Impact factor: 22.113

4.  Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Authors:  Gordon Chan; Demetrios Kalaitzidis; Tatiana Usenko; Jeffery L Kutok; Wentian Yang; M Golam Mohi; Benjamin G Neel
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

5.  Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk.

Authors:  Karl Staser; Su-Jung Park; Steven D Rhodes; Yi Zeng; Yong Zheng He; Matthew A Shew; Jeffrey R Gehlhausen; Donna Cerabona; Keshav Menon; Shi Chen; Zejin Sun; Jin Yuan; David A Ingram; Grzegorz Nalepa; Feng-Chun Yang; D Wade Clapp
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

6.  Cul4A is required for hematopoietic cell viability and its deficiency leads to apoptosis.

Authors:  David L Waning; Binghui Li; Nan Jia; Yahaira Naaldijk; W Scott Goebel; Harm HogenEsch; Kristin T Chun
Journal:  Blood       Date:  2008-03-13       Impact factor: 22.113

Review 7.  The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease.

Authors:  Timothy R Hercus; Daniel Thomas; Mark A Guthridge; Paul G Ekert; Jack King-Scott; Michael W Parker; Angel F Lopez
Journal:  Blood       Date:  2009-05-12       Impact factor: 22.113

8.  A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene.

Authors:  Bin Yin; Ruud Delwel; Peter J Valk; Margaret R Wallace; Mignon L Loh; Kevin M Shannon; David A Largaespada
Journal:  Blood       Date:  2008-10-23       Impact factor: 22.113

9.  Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.

Authors:  Nikesh Kotecha; Nikki J Flores; Jonathan M Irish; Erin F Simonds; Debbie S Sakai; Sophie Archambeault; Ernesto Diaz-Flores; Marc Coram; Kevin M Shannon; Garry P Nolan; Mignon L Loh
Journal:  Cancer Cell       Date:  2008-10-07       Impact factor: 31.743

10.  Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells.

Authors:  E Camilla Forsberg; Emmanuelle Passegué; Susan S Prohaska; Amy J Wagers; Martina Koeva; Joshua M Stuart; Irving L Weissman
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.